Intimation of the closure of Trading Window

Novartis India Limited September 30, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip code: 500672 Sub.: Intimation of the meeting of the Board of Directors of Novartis India Limited ('the Company') and the Closure of Trading Window. Dear Sir/ Madam, Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of Novartis India Limited ("the Company") is scheduled to be held on Tuesday, November 03, 2026, inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Further, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company, read with the applicable provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of the Company by Designated Persons/ Insiders/ Connected Persons and their immediate relatives shall remain closed with effect from October 01, 2026, and shall reopen 48 hours after the declaration of the aforesaid Financial Results to the Stock Exchange (“BSE Limited”). The above information is also being made available on the website of the Company at https://nilpharma.co.in/ You are requested to take note of the above information. Thank You. Yours Sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer M. No. A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in